Results remain solid but not spectacular. I had thought that the issue of customers changing to "in-house" testing was largely behind us but apparently not. Haven't listened to the CC (it wouldn't load last night) but am looking to hear news about CRC business segment and adoption of new tests. If adoption is robust, we should look forward to a brisk 2016, when the new pathology reimbursement kicks in.
All of those could be true but I think bigger things are planned for this little microcap. We've been a leader in new genetics testing (and our liquid biopsy is several years ahead of competitors) and the prospect of partnering/licensing is now a reality. Should either come to pass, the revenue growth and income growth will be tremendous and the partners will have huge opportunities to make money. I'm looking for good news to be steady and attention grabbing moving forward for the next 6-8 quarters.
Those are old estimates that will surely fall if we beat street expectations on 7/23. Things are shaping up nicely with 20%+ YOY growth, break even revenues and now and 8% reimbursement premium to add to the mix. I expect the Pathlogic addition to continue to provide upside surprise,traction on the new suite of liquid pathology tests, and further business development. Watch for upside guidance for the rest of this year, new analysis of revenues and earnings after the quarterly report, and new price target(s) closer to $10/share in the near term.
Yup Red, this is one of my "buy and hold" positions, a company I've now had for 9 years and will hold until the game is over (buyout) or so impossibly high that I can't resist. I have seen a few trading sessions like this before, but only 2 or 3 times in the entire history of the company. It has ALWAYS been a good sign and this happening so far out from the earnings date is very exciting to me. I just wished I had followed my gut a couple of weeks ago and exited out of another holding and put it into this at $4 and change.
That IS some big news for the industry and adding 8% to our margins is tantamount to 3-4cent/share profit given our current margin (ballpark). a quick look, however, does not show the same pop for our competitors, so there may be something else up.
I usually don't comment on day to day changes in volume and price, but today's open and skyrocket advance is remarkable. Something is up and I'm hoping that the news is simply how well the quarter went (which leaves more room for upside on business development) but I'm happy about anything that brings us forward!
Response Genetics is plunging into oblivion. I have heard little from NEO regarding their marketing of the RGDX tests and the revenue it generates or the royalties it pays. I am curious if it is time for NEO to simply buy RGDX out. If they have a CLIA lab as part of their property, it might be a good buy as the co. now has a market cap of only $5 million. Thoughts?
Friday's volume was a reflection of NEO being added to the Russell 3000. The volume was well-managed by the market makers, otherwise such a huge buy would have meant a skyrocketing price.
If $1100/oz gold is "the darkest before the storm" I would be quite happy. There is no model that I know of that provides an alternative to "the inflationary cycle" that has ALWAYS happened and will happen again, bringing gold to new highs. The QE process has generated a new trajectory of the inflationary cycle, lengthening it and mitigating the slope of inflation, but the cycle will eventually play out. $5 loaves of bread, $6/gallon gas and ground beef at $5/lb is in everyone's future,
New board members, new stock options. Both of these look good, IMO. The new board members have bona fides and the CRC specialist looks to be a real addition to the line up of experts guiding the co. The vote on approval of new stock options looks reasonable with regard to the number of shares allowed and may be a good sign for employee incentives.
NeoGenomics Launches Twelve NeoLAB™ "Liquid Biopsy" Tests for Hematologic Diseases.
This looks like a very good suite of tests, targeted for a large at risk population (acute leukemia and related disorders) and has the market qualities that are attractive including convenience for patients, pricing (versus an invasive procedure), and follow-up monitoring uses. I will be very interested in hearing from mgmt about adoption over the next 4 quarters. This could easily become a $25 million/year level suite of tests. Too bad there is no surveillance akin to prescription writing that can give us an outside count of the number of tests ordered.
BRLI is a modestly bigger genetics testing lab in the same space. I thought the buyout price was low, only 2X trailing revenues for BRLI despite their healthy profitability. I hope we get a better price if/when a suitor comes along.
All things considered, we're still pretty thinly traded. Yahoo charting now shows buy side and sell side trades and the sell side trades are small. Looks like retail investors selling and the bigger chunks are buy side. I don't think in terms of mounting buy pressure but any good news on the business development will generate buy side pressure.